Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease

This study is testing a cell therapy called iNSC-DAP — derived from a patient's own induced neural stem cells — injected into the brain as a potential treatment for Parkinson's disease. It is an early-phase study primarily focused on safety. **You may be eligible if...** - You are between 30 and 85 years old - You have been diagnosed with Parkinson's disease according to standard medical criteria - You have had Parkinson's for more than 3 years - Your disease is at Hoehn and Yahr Stage 4 or below when your medication is working ("on" state) - You respond to levodopa treatment (at least 30% improvement in motor symptoms) **You may NOT be eligible if...** - You have atypical or secondary Parkinsonism (not classic Parkinson's disease) - You have other serious brain or nervous system diseases - You have significant psychiatric illness or cognitive impairment (MMSE below 24) - You have had prior brain surgery - You take blood thinners long-term and cannot stop Talk to your doctor to see if this trial is right for you.